- What changed
- Enveda secured a $311 million Series E funding round at a $2 billion valuation to advance nature-derived drug candidates into clinical trials.
- Why you should care
- Venture capital continues to flow into applied biotech startups leveraging AI for drug discovery.
- Your move
- Watch. Monitor ongoing funding trends in AI drug discovery to gauge market validation.
- What to watch next
- Announcements regarding clinical trial results for Enveda drug candidates.
- Event
- business move
- Event date
- Sep 23, 2026
- Relevant to
- General AI readers